Published: 2023 | Last reviewed: May 2026
Screening Anticancer Drugs with NCI Lines
Key Takeaways
- Research Applications
- • High-throughput drug screening
• Mechanism of action studies
• Drug resistance evaluation - Cell Line Diversity
- • Multiple cancer types represented
• Various tissue origins
• Different genetic profiles - Validation
- • Authentication guaranteed
• Mycoplasma-free certification
• Documented passage history
Research Applications in Drug Discovery
The NCI-60 cell line panel represents a powerful tool in cancer drug discovery, offering researchers a standardized platform for initial drug screening. Key cell lines like A549 cells for lung cancer and MCF-7 cells for breast cancer research have become cornerstone models in high-throughput screening campaigns. These validated cell lines enable researchers to rapidly assess thousands of compounds for anticancer activity.
Our validated cell lines, including HepG2 cells and LNCaP cells, are extensively used in drug discovery pipelines to:
- Evaluate dose-response relationships
- Determine IC50 values
- Assess cancer-type specificity
- Study cytotoxicity profiles
Each cell line in our portfolio undergoes rigorous authentication testing and mycoplasma screening, ensuring reliable and reproducible results in your drug discovery programs. Our standardized protocols and detailed documentation support Good Laboratory Practice (GLP) compliance in drug development workflows.
Comprehensive Cell Line Diversity
Cancer heterogeneity demands diverse cellular models. Our NCI line collection spans multiple tissue origins and genetic backgrounds, providing researchers with comprehensive screening capabilities. From breast cancer to brain cancer models, each cell line offers unique insights into cancer biology.
Key Tissue Types Available:
Featured Cell Lines:
• HeLa cells - Cervical cancer • HepG2 cells - Liver cancer • LNCaP cells - Prostate cancer • A549 cells - Lung cancer
Each cell line in our portfolio represents distinct molecular profiles and drug response patterns. For instance, our MCF-7 cells are widely used for hormone-dependent breast cancer studies, while MDA-MB-231 cells represent triple-negative breast cancer models. This diversity enables researchers to:
- Compare drug responses across multiple cancer types
- Identify tissue-specific drug sensitivities
- Study mechanism of action in different cellular contexts
- Evaluate targeted therapy approaches
Quality Validation and Authentication
At Cytion, we understand that cell line authentication is crucial for reliable research outcomes. Every NCI cell line in our portfolio undergoes comprehensive validation protocols, ensuring the highest standards of quality and reproducibility.
Authentication Testing
All cell lines undergo authentication testing, including STR profiling and species verification, providing researchers with confirmed cell line identity.
Contamination Screening
Regular mycoplasma testing and sterility checks ensure our cell lines are free from biological contamination.
Growth Characteristics
Each batch is monitored for proper morphology, growth rates, and phenotypic stability across passages.
To maintain the highest quality standards in your drug screening programs, we recommend regular cell line authentication and contamination testing. Our cell banking services can help establish and maintain validated master cell banks for your critical cell lines.
NCI Cell Line Screening: Key Components
Research
- Applications
Drug Screening
- MOA Studies
Resistance Testing
- Cell Line
Diversity
- Multiple Cancer Types
Various Origins
- Genetic Profiles
Quality
- Validation
Advancing Cancer Research Through Validated Cell Models
Ready to advance your cancer drug screening research? Contact our team for:
- Custom cell line panels for your specific research needs
- Technical support and protocol optimization
- Authentication and quality control services